Editas Medicine, Inc. (EDIT) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "EDIT"
      ],
      "issuer_cik": "0001650664",
      "owner_cik": "0001742084",
      "accession_number": "0001742084-26-000003",
      "form_type": "4",
      "filing_date": "2026-09-04",
      "period_of_report": "2026-09-03",
      "issuer_name": "Editas Medicine, Inc.",
      "issuer_trading_symbol": "EDIT",
      "owner_name": "O'Neill Gilmore Neil",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CEO",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-03",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 5124,
      "transaction_price_per_share": 3.0372,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 243189,
      "transaction_value": 15562.612799999999,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person."
        },
        {
          "id": "F2",
          "description": "This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."
        }
      ]
    },
    {
      "tickers": [
        "EDIT"
      ],
      "issuer_cik": "0001650664",
      "owner_cik": "0001985604",
      "accession_number": "0001985604-26-000003",
      "form_type": "4",
      "filing_date": "2026-09-04",
      "period_of_report": "2026-09-03",
      "issuer_name": "Editas Medicine, Inc.",
      "issuer_trading_symbol": "EDIT",
      "owner_name": "Burkly Linda",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "EVP, CHIEF SCIENTIFIC OFFICER",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-03",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 709,
      "transaction_price_per_share": 3.0372,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 61660,
      "transaction_value": 2153.3748,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person."
        },
        {
          "id": "F2",
          "description": "This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.